Información del artículo
El Texto completo está disponible en PDF
References
[1.]
A. Ceriello, M. Hanefeld, L. Leiter, L. Monnier, A. Moses, D. Owens, et al.
Postprandial glucose regulation and diabetic complications.
Arch Intern Med, 164 (2004), pp. 2090-2095
[2.]
F. De Vegt, J.M. Dekker, H.G. Ruhè, C.D.A. Stehouwer, G.B.L.M. Nijpels, R.J. Heine.
Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population : the Hoorn Study.
Diabetologia, 42 (1999), pp. 926-931
[3.]
R.P. Donahue, R.D. Abbott, D.M. Reed, K. Yano.
Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program.
Diabetes, 36 (1987), pp. 689-692
[4.]
L.P. Lowe, K. Liu, P. Greenland, B.E. Metzger, A.R. Dyer, J. Stamler.
Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study.
Diabetes Care, 20 (1997), pp. 163-169
[5.]
The DECODE study group, on behalf of the European Diabetes Epidemiology Group.
Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria.
Lancet, 354 (1999), pp. 617-621
[6.]
M. Coutinho, H.C. Gerstein, Y. Wang, S. Yusuf.
The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed fro 12.4 years.
Diabetes Care, 22 (1999), pp. 233-240
[7.]
B. Balkau, M. Shipley, R.J. Jarrett, K. Pyörälä, M. Pyörälä, A. Forhan, et al.
High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study.
Diabetes Care, 21 (1998), pp. 360-367
[8.]
M. Hanefeld, S. Fischer, U. Julius, J. Schulze, U. Schwanebeck, H. Schmechel, The DIS Group, et al.
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.
Diabetologia, 39 (1996), pp. 1577-1583
[9.]
F. Cavalot, A. Petrelli, M. Traversa, K. Bonomo, E. Fiora, M. Conti, et al.
Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.
J Clin Endocrinol Metab, 91 (2006), pp. 813-819
[10.]
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso, STOP-NIDDM Trail Research Group.
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet, 359 (2002), pp. 2072-2077
[11.]
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso, STOP-NIDDM Trail Research Group.
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
JAMA, 290 (2003), pp. 486-494
[12.]
U. Zeymer, A. Schwarzmaier-D’Assie, D. Petzinna, J.L. Chiasson, STOP-NIDDM Trial Research Group.
Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOPNIDDM trial electrocardiography substudy.
Eur J Cardiovasc Prev Rehabil, 11 (2004), pp. 412-415
[13.]
M. Hanefeld, J.L. Chiasson, C. Koehler, E. Henkel, F. Schaper, T. Temelkova- Kurktschiev.
Acarbose slows progression of intimamedia thickness of the carotid arteries in subjects with impaired glucose tolerance.
Stroke, 35 (2004), pp. 1073-1078
[14.]
M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, M. Rupp.
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
Eur Heart J, 25 (2004), pp. 10-16
[15.]
K. Espósito, D. Giugliano, F. Nappo, R. Marfella.
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Circulation, 29 (2004), pp. 2978-2984
[16.]
A. Ceriello.
Postprandial hyperglycemia and diabetes complications: is it time to treat?.
Diabetes, 54 (2005), pp. 1-7
[17.]
A. Ceriello, N. Bortolotti, E. Motz, A. Crescentini, S. Lizzio, A. Russo, et al.
Meal-generated oxidative stress in type 2 diabetic patients.
Diabetes Care, 21 (1998), pp. 1529-1533
[18.]
A. Ceriello, L. Quagliaro, B. Catone, R. Pascon, M. Piazzola, B. Bais, et al.
Role of hyperglycemia in nitrotyrosine postprandial generation.
Diabetes Care, 25 (2002), pp. 1439-1443
[19.]
A. Ceriello, N. Bortolotti, E. Motz, C. Pieri, M. Marra, L. Tonutti, et al.
Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia.
Metabolism, 48 (1999), pp. 1503-1508
[20.]
L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.P. Cristol, et al.
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.
JAMA, 295 (2006), pp. 1681-1687
[21.]
A. Ceriello, C. Taboga, L. Tonutti, L. Quagliaro, L. Piconi, B. Bais, et al.
Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of shortand long-term simvastatin treatment.
Circulation, 106 (2002), pp. 1211-1218
[22.]
A. Ceriello, L. Quagliaro, L. Piconi, R. Assaloni, R. Da Ros, A. Maier, et al.
Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment.
Diabetes, 53 (2004), pp. 701-710
[23.]
A. Ceriello.
New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy.
Diabetes Care, 26 (2003), pp. 1589-1596
[24.]
R. Assaloni, R. Da Ros, L. Quagliaro, L. Piconi, A. Maier, G. Zuodar, et al.
Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients.
Diabetologia, 48 (2005), pp. 1919-1924
[25.]
A. Ceriello, L. Piconi, L. Quagliaro, Y. Wang, C.A. Schnabel, J.A. Ruggles, et al.
Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.
Diabetes Care, 28 (2005), pp. 632-637
[26.]
D. Manzella, R. Grella, A.M. Abbatecola, G. Paolisso.
Repaglinide administration improves brachial reactivity in type 2 diabetic patients.
Diabetes Care, 28 (2005), pp. 366-371
[27.]
A. Ceriello, A. Cavarape, L. Martinelli, R. Da Ros, G. Marra, L. Quagliaro, et al.
The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart.
Diabet Med, 21 (2004), pp. 171-175
[28.]
M. Shimabukuro, N. Higa, N. Takasu, T. Tagawa, S. Ueda.
A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
Diabet Med, 21 (2004), pp. 983-986
[29.]
M. Shimabukuro, N. Higa, I. Chinen, K. Yamakawa, N. Takasu.
Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study.
J Clin Endocrinol Metab, 91 (2006), pp. 837-842
[30.]
R. Scognamiglio, C. Negut, S.V. De Kreutzenberg, A. Tiengo, A. Avogaro.
Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients.
Diabetes Care, 29 (2006), pp. 95-100
[31.]
G. Rudofsky Jr, P. Reismann, S. Schiekofer, D. Petrov, M. Eynatten, P.M. Humpert, et al.
Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs.
Horm Metab Res, 36 (2004), pp. 630-638
[32.]
M.R. Taskinen, S. Lahdenpera, M. Syvänne.
New insights into lipid metabolism in non-insulin-dependent diabetes mellitus.
Ann Med, 28 (1996), pp. 335-340
[33.]
A. Hamsten, J. Björkegren, S. Boquist, L. Nilsson, G. Ruotolo, P. Eriksson, et al.
Postprandial lipaemia and coronary heart disease.
Atherosclerosis, 11 (1998), pp. 141-149
[34.]
E. Cavallero, C. Dachet, D. Neufcou, E. Wirquin, D. Mathe, B. Jacotot.
Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels.
Metabolism, 43 (1994), pp. 270-278
[35.]
R.J. Heine, J.M. Dekker.
Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease.
Diabetologia, 45 (2002), pp. 461-465
[36.]
R. De Caterina.
Endothelial dysfunctions: common denominators in vascular disease.
Curr Opin Lipidol, 11 (2000), pp. 9-23
[37.]
J.H. Bae, E. Bassenge, K.B. Kim, Y.N. Kim, K.S. Kim, H.J. Lee, et al.
Hypertriglyceridemia impairs endothelial function by enhanced oxidant stress.
Atherosclerosis, 155 (2001), pp. 517-523
[38.]
M. Brownlee.
Biochemistry and molecular cell biology of diabetic complications.
Nature, 414 (2001), pp. 813-820
[39.]
X. Du, D. Edelstein, S. Obici, N. Higham, M.H. Zou, M. Brownlee.
Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation.
J Clin Invest, 116 (2006), pp. 1071-1080
[40.]
E. Bonora, G. Corrao, V. Bagnardi, A. Ceriello, M. Comaschi, P. Montanari, et al.
Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus.
Diabetologia, 49 (2006), pp. 846-854
Copyright © 2009. Sociedad Española de Endocrinología y Nutrición
